Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension by Schuster, Cornelia et al.
Clinical Efficacy and Safety of Bevacizumab Monotherapy
in Patients with Metastatic Melanoma: Predictive
Importance of Induced Early Hypertension
Cornelia Schuster1,2,3, Hans P. Eikesdal1, Hanne Puntervoll2,3, Ju¨rgen Geisler4,5, Stephanie Geisler1,
Daniel Heinrich4,5, Anders Molven2,3, Per E. Lønning1, Lars A. Akslen2,3, Oddbjørn Straume1*
1Department of Oncology, Haukeland University Hospital, Bergen, Norway, 2 Section for Pathology, The Gade Institute, University of Bergen, Bergen, Norway,
3Department of Pathology, Haukeland University Hospital, Bergen, Norway, 4Division of Clinical Medicine and Laboratory Sciences, Institute of Clinical Medicine,
University of Oslo, Oslo, Norway, 5Department of Oncology, Akershus University Hospital, Lørenskog, Norway
Abstract
Background: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of
bevacizumab monotherapy in patients with metastatic melanoma.
Methods and Findings: Thirty-five patients with metastatic melanoma in progression were enrolled in this phase II, single
arm clinical trial. Each patient received bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease
progression occurred. Clinical efficacy was evaluated as objective response, disease control (DC), and survival. We observed
one complete (3%) and 5 partial (14%) responses. In addition, 5 patients experienced stable disease .6 months (14%) while
24 patients had progressive disease (PD, 69%), corresponding to a total DC at 6 months in 11 out of 35 patients (31%).
Median progression free survival (PFS) was 2.14 months and median overall survival (OS) was 9 months (1.12–49). Seven of
the 11 patients experiencing DC developed early hypertension (,2 months) compared to 3/24 of patients with PD
(P= 0.001), and hypertension was associated with PFS (P= 0.005) and OS (P= 0.013).
Conclusion: Bevacizumab monotherapy demonstrated promising clinical efficacy in patients with metastatic melanoma
with disease control in 31% of the patients. Induced early hypertension was a marker for clinical efficacy of bevacizumab.
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Introduction
Metastatic melanoma is a non-curable condition with limited
therapeutic options. Until recently, high dose interleukin-2 and
dacarbazine were the only regimens in routine use, with
response rates observed in about 10% of unselected pa-
tients[1–3]. While the human monoclonal anti CTLA-4
antibody ipilimumab was recently shown to cause a survival
benefit in stage IV melanoma [4], the drug was found active in
a fraction of patients only. Improved survival was also reported
for treatment of metastatic melanoma patients carrying a
specific BRAF mutation (,40% of all melanoma patients) using
the highly selective V600E kinase inhibitor vemurafenib [5].
Thus, while selected patients may benefit from novel treatment
options, effective treatment is still not available for a high
proportion of melanoma patients. In addition, patients benefit-
ting from conventional (interleukin-2 or dacarbazine) as well as
novel (ipilimumab and vemurafenib) therapeutic strategies
develop acquired therapy resistance over time, underlining the
need for alternative treatment options.
Melanoma progression and metastasis is dependent on angio-
genesis [6] and the vascular endothelial growth factor (VEGF)
system seems to be particularly important [7,8]. The humanized
monoclonal antibody bevacizumab is a highly specific inhibitor of
VEGF-A. Bevacizumab significantly prolonged overall survival
when given in combination with chemotherapy in colorectal
cancer [9] and in non-small cell lung cancer [10]. In addition,
responses have been reported in clinical trials evaluating
bevacizumab in combination with interferon alpha 2B [11],
interferon alpha 2A [12] or chemotherapy[13–15] in patients with
metastatic melanoma. Administered as monotherapy, bevacizu-
mab prolonged time to progression given in patients suffering from
metastatic kidney cancer [16].
To the best of our knowledge, no clinical trials have been
published specifically testing the clinical efficacy of bevacizumab
monotherapy in metastatic melanoma. Here, we report the results
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from a phase II trial evaluating clinical efficacy of bevacizumab
monotherapy in patients with metastatic melanomas.
Methods
Ethics
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and the International
Conference on Harmonization of Good Clinical Practice. The
protocol was approved by the Regional Ethics Committee and the
Norwegian Medicines Agency. All participating patients provided
signed informed consent before enrolment.
Patients
Between April 2005 and August 2009, 52 patients were
screened. Eligibility criteria included histologically confirmed
unresectable metastatic melanoma in progression; age .18 years;
WHO performance status 0–2; clinically and/or radiographically
measurable disease according to RECIST; .4 weeks since
adjuvant interferon; no prior interferon or interleukin for
metastatic disease; recovered from prior chemotherapy; no major
surgery within 28 days; no known brain metastases; absolute
neutrophils .1.06109/L; platelets .1006109/L; bilirubin, cre-
atinine, INR ,1.56upper normal limit; no symptomatic conges-
tive heart failure, angina pectoris, cardiac arrhythmia, history of
thrombosis, uncontrolled hypertension, full dose coumarin-derived
anticoagulants or NSAIDS.
Study Design
This was a phase II, open-label, single-arm, single institution
clinical trial (ClinicalTrials.gov Identifier: NCT00139360), per-
formed at the Haukeland University Hospital, Bergen Norway.
The full protocol is available online as supporting information
(Protocol S1). The primary objective was to determine clinical
efficacy, as measured by objective response (OR) and disease
control (DC) defined as stable disease (with or without an
objective tumor shrinkage) after 6 months on therapy.
Secondary objectives were to estimate time to progression
(TTP), progression free survival (PFS) and overall survival (OS).
Finally, we aimed at exploring potential relations between side
effects, including acquired hypertension as well as BRAF/NRAS
mutation status as potential predictive factors to clinical
response.
Initially, patients were included after confirmed progression on
standard first line treatment with dacarbazine (level A, n = 15).
Only after objective response was observed on bevacizumab
monotherapy, all new patients were subsequently enrolled for first
line treatment with bevacizumab (Level B, 20 patients) (Flow
diagram S1).
Each treatment cycle consisted of bevacizumab 10 mg/kg IV
on day 1 in a 2-weekly schedule. Thus, the chosen dose was higher
than the doses used in bevacizumab therapies for normalization of
tumor vasculature (5 mg/kg q14d) [17,18] and in line with the
dosing of bevacizumab monotherapy used in advanced renal
cancer where a survival benefit was indicated (10 mg/kg q14d)
[16]. Drug toxicity was assessed after each cycle, while the
response rate was evaluated after every 4 cycles. Patients with
disease progression or unmanageable toxicity were discontinued
and offered further melanoma treatment at the clinician’s
discretion. Standard clinical parameters (routine biochemistry,
urine analysis, blood pressure, WHO performance status) as well
as the mutational status for BRAF and NRAS were assessed for
subsequent correlation with clinical outcome.
Response Assessment and Toxicity
The primary endpoint was objective response (OR) defined as
complete response (CR) or partial response (PR) according to
RECIST [19] as well as disease control (DC) defined as CR + PR
and including stable disease (SD) for more than 6 months. Disease
stabilization is considered beneficial to patients experiencing
melanoma progression at the time of inclusion and DC is
frequently included as an additional statistical endpoint in trials
investigating new antiangiogenic drugs in which therapeutic
activity and clinical benefit are present, even in the absence of
radiological tumor shrinkage[20–22]. Importantly, all patients
were in clinical and/or radiological progression at the time of
inclusion. OR and DC were calculated on the basis of investigator
assessment. While confirmed response after 4 weeks was not a
protocol requirement, all patients achieving an objective response
had a subsequent confirmation at the next routine visit every 8
weeks. Patients with clinical disease progression or death due to
melanoma before first radiological progression were recorded as
progressive disease (PD), and best overall response (BOR) was not
available in these patients. TTP was defined as the time from
enrolment to disease progression or death due to melanoma.
Adverse events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse events,
version 3.0 [23], and were recorded by each 2-week cycle.
Tissue Sampling and DNA Analysis
To evaluate a possible relationship between the most frequent
genetic alterations in melanoma and treatment outcome, a
targeted mutational analysis was performed for BRAF and NRAS.
Tumor tissue was manually dissected from 3 paraffin sections
(10 mm) before extracting DNA with the E.Z.N.A Tissue DNA Kit
(Omega Bio-Tek, Inc., Norcross, GA, USA). BRAF exon 11 and
15, as well as NRAS exon 1 and 2 were amplified by PCR, and
screened for mutations by direct Sanger sequencing. Primers are
described elsewhere[24–26]. The sequence reactions were per-
formed using the Terminator Cycle Sequencing kit, BigDye
version 1.1 (Applied Biosystems, Foster City, CA, USA ), and were
analyzed on an ABI PRISMH 3100 Genetic Analyzer, applying
Sequencing Analysis software, version 3.7 (both from Applied
Biosystems).
Statistical Methods
The optimal two-stage design for phase II clinical trials
proposed by Simon [27] was used. The co-primary endpoint
DC was used to determine sample size. It was assumed that the
new regimen would have a DC rate of 30%. A DC rate of 10% or
lower was considered not superior to standard first-line therapy
(dacarbazine). With 10% type I error rate and 90% power a total
number of 35 patients were entered in the trial.
Two sample t-test and Mann-Whitney U test were used to
compare the distribution of continuous variables between two
groups such as responders and non-responders. Kaplan-Meier
estimates were constructed for time-to-event endpoints such as
PFS and OS, and log rank-test was applied for testing differences.
Due to the small sample size and the nature of the phase II study,
the above analyses were considered exploratory and the results
need to be confirmed in future large-scale studies.
Results
Patients
Between April 2005 and August 2009, 52 patients with
metastatic or unresectable melanoma in progression were screened
and 35 patients were enrolled in this trial. The seventeen screening
Bevacizumab Monotherapy in Malignant Melanoma
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failures were most frequently due to brain metastases, co
morbidity, or withdrawal of informed consent (Fig 1). During
recruitment at level A, 15 patients received bevacizumab as
second/third line treatment (after DTIC failure) while additional
20 more patients were included during recruitment level B (first
line therapy bevacizumab). Patient characteristics are listed in
Table 1.
Responses, PFS and Survival
In the study population of 35 patients, we observed 1 CR
(3%), 5 PR (14%), and 5 SD .6 months (14%). Thus, 24
patients (69%) progressed on therapy, including three patients
who progressed clinically before radiological tumor evaluation.
Best overall response (BOR), measured as the change in the
sum of largest diameter of the target lesions is illustrated in
Figure 2A. Duration of the responses in relation to patient
characteristics is illustrated in Figure 2B. Tumor responses were
observed at metastatic sites such as skin, lymph nodes, lung,
liver and ovaries (Fig 3).
At 6 months of follow up, 11/35 (31)% of the patients had no
sign of melanoma progression. This proportion was 8/20 for the
first line patients and 3/15 for the second/third line patients,
respectively. By August 2011, median PFS was 2.14 months
whereas mean PFS was 7.7 months (range 0.8–30 months), with a
median overall survival of 9 months (mean: 13, range: 1.1–49)
(Fig 4 A and B). The median number of cycles was 4 (mean: 14,
range: 1.0–64). No patients died of causes other than melanoma
progression. Six of the patients are still alive, and 5 of them are still
on bevacizumab treatment without signs of progression 15–30
months after starting bevacizumab.
Seven of 11 patients with DC developed early hypertension
(EH) as defined by CTCAEv3.0. In contrast, only three of 24
(12.5%) patients with progressive disease (PD) developed EH (Chi-
square test p,0.001). Median time to progression for patients who
developed EH following bevacizumab treatment was 11.4 months
Figure 1. Study flow diagram. Between April 2005 and August 2009, 52 patients with metastatic melanoma were screened. Thirty-five of those
patients were eligible according to inclusion criteria and received the study drug.
doi:10.1371/journal.pone.0038364.g001
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compared to 2.0 months in normotensive patients. EH was
significantly associated with prolonged PFS (log rank p= 0.001,
Fig 4C) as well as improved overall survival (log rank p= 0.005,
Fig 4D). To explore the possible association between the use of
different antihypertensive drugs and disease progression we
observed that 6 of 7 patients on concomitant beta blockers
experienced DC following treatment with bevacizumab mono-
therapy. In comparison, 3/6 patients who used antihypertensive
drugs other than beta blockers, or 2/22 who used no antihyper-
tensive drugs experienced DC (Chi square test p,0.001).
Stage M1a and b disease was significantly associated with DC
(7/7) as compared with M1c disease (4/28; Chi-square test
p,0.001). Similarly, 9 of 14 patients with normal levels of lactate
dehydrogenase (LDH) at baseline had DC as compared with 2 out
of 21 with increased LDH (Chi-square test p= 0.001). No
significant correlations were found between DC, OR, PFS or
OS and BRAF or NRAS mutation status, performance status, sex or
age.
Safety
Bevacizumab monotherapy, given as 10 mg/kg q14d IV was in
general well tolerated by the patients. No treatment related deaths
were recorded. Treatment was stopped in two patients with
CTCAE grade 4 toxicity (1 anaphylactic shock at cycle 2 and 1
lung embolus at cycle 5) and in one patient with grade 3
gastrointestinal toxicity (partial obstruction due to disease
progression at cycle 1). Treatment was interrupted in one patient
with grade 3 toxicity due to symptomatic left ventricular systolic
dysfunction after 16 cycles. All adverse events are listed in Table
S1 (online only). No dose reduction, interruption or postponement
due to fatigue or hypertension was necessary and no hemorrhage
was observed. Bevacizumab was delayed until proteinuria was
,2 g/24 h in three patients (,4 weeks), but no treatment was
stopped permanently due to proteinuria.
Hypertension according to CTCAEv3.0 was observed in 14
(40%) patients after initiation of bevacizumab. Grade 1:4 (11%),
grade 2:3 (9%) and grade 3:7 (20%), respectively. Median time to
induced hypertension was 43 days (mean: 59, range: 27–239). We
defined early hypertension (EH) as hypertension $ grade I
occurring before 1st tumor response evaluation at 8 weeks. EH was
recorded in 10 patients whereas 4 patients developed hypertension
at a later time point. As listed in Table 1, 8 (23%) of the patients
were treated for hypertension at the time of inclusion. Type of
antihypertensive drugs used is listed in Table S2.
Discussion
While some phase II studies have evaluated the use of
bevacizumab in concert with interferon alpha 2B [11,28],
interferon alpha 2A [12] or chemotherapy [13,14], to the best of
our knowledge this is the first study evaluating bevacizumab
monotherapy in metastatic malignant melanoma. Our results
provide a proof-of-principle that bevacizumab monotherapy is
active in metastatic melanoma with a disease control rate of 31%
and a 6 months PFS rate of 31%. In consistency with our finding,
a recently published study of the multi kinase inhibitor axitinib
(including VEGF receptor 1, 2 and 3) given as monotherapy
showed a OR rate of 18.8% and a DC rate of 37.5% in a similar
patient population [29]. These results are strikingly in line with
ours and are in support of a significant subgroup of melanoma
patients being susceptible to anti-VEGF strategies. Although not
meeting the primary objective of increased median progression
free survival, a recently published placebo controlled randomized
phase II study showed encouraging overall survival data in
metastatic melanoma patients treated with carboplatin and
paclitaxel 6 bevacizumab [15]. In contrast to our present
findings, the patients who benefitted most from that combination
were those with increased LDH and M1C disease, possibly
indicating different sensitivity between patients groups to combi-
nation therapy and monotherapy.
In metastatic melanoma new treatment options have recently
emerged targeting BRAF [5] or CTLA-4 [4] showing improved
overall survival, but these treatments are associated with significant
toxicities and costs. In addition, for BRAF negative patients or
patients with non-immunogenic disease only limited effective
treatment options are available. Significantly, in our study there
Table 1. Baseline Demographic and Clinical Characteristics of
Patients.
Characteristics Study cohort (n=35)
Age, years
Median 63
Range 26–77
Sex - No. (%)
Male 19 (54)
Female 16 (46)
Stage - No. (%)
M1a 1 (3)
M1b 6 (17)
M1c 28 (80)
LDH.ULN - No. (%)
No 14 (40)
Yes 21 (60)
WHO performance status - No. (%)
0 28 (80)
1 7 (20)
Previous systemic treatments - No. (%)
0 20 (57)
1 14 (40)
2 1 (3)
Hypertension before treatment - No. (%)
No 27 (77)
Yes 8 (23)
BRAF exon 15 mutation – No. (%)
Wild type 20 (57)
V600E 13 (37)
V600K 1 (3)
V600D/V600E Double mutation 1 (3)
NRAS exon 2 mutation - No. (%)
Wild type 24 (69)
Q61R 4 (11)
Q61L 2 (6)
Q61K 3 (9)
E62E 1 (3)
Not amplifiable 1 (3)
Abbreviations: LDH, lactate dehydrogenase; ULN, upper limit of normal; WHO,
World Health Organization.
doi:10.1371/journal.pone.0038364.t001
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Figure 2. Patterns of response to treatment with bevacizumab monotherapy in metastatic malignant melanoma patients. Panel A
shows the best overall response for 32 patients who had undergone at least one tumor assessment measured as the change from baseline in the sum
of the largest diameters of each target lesion. Three patients progressed clinically and/or biochemically before first tumor assessment, and are not
shown. Negative values indicate tumor shrinkage, and the dashed lines indicate the threshold for a partial response (PR) and progressive disease (PD),
respectively. Panel B shows the duration and characteristics of the responses in each patient.
doi:10.1371/journal.pone.0038364.g002
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was a subset of patients (14%) showing long-term survival on
treatment (.2 years), independent of BRAF or NRAS mutational
status.
Predictive markers for response to antiangiogenic treatment
are urgently needed to guide clinical decision making and to
target therapy towards well selected subgroups of patients. The
present lack of useful predictive biomarkers decrease the
likelihood of benefits, cost-effectiveness and therapeutic out-
comes [14,30]. We provide evidence that the clinical benefit of
bevacizumab monotherapy in metastatic melanoma is almost
exclusively limited to those patients who develop early
hypertension during treatment. This can in part be explained
by the fact that some non-responders did not have sufficient
time on bevacizumab to develop hypertension. Still, most of the
hypertensive patients (10/14) were recorded with hypertension
before the 1st tumor evaluation in week 8 (early hypertension).
This phenomenon has been reported for several antiangiogenic
drugs [30], and early onset hypertension is one of few markers
at the present have been found to predict response to
antiangiogenic drugs [30,31].
The causal mechanism behind induced hypertension by
antiangiogenic drugs is still elusive. VEGF upregulates nitric
oxide [32] and prostacyclin [33], leading to vasodilatation,
which is counteracted by bevacizumab. Also, the secondary
hypotension following vascular permeability and leakiness
caused by VEGF is counteracted by VEGF inhibition [34].
Figure 3. Computed tomography showing partial responses in three different patients at baseline and at 12 months. Panel A shows
ovarian metastases in a 43 years old woman. Panel B shows lung metastases in a 50 years old man. Panel C shows liver metastases and pleural
effusion (*) in a 70 years old man. Arrows show the largest diameter of the lesions.
doi:10.1371/journal.pone.0038364.g003
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The angiogenic effect of players in the sympathetic nervous
system associated with hypertension like norepinephrine (NE),
has been reported [35]. Induction of VEGF and HIF-1a
expression by NE was completely abolished by the beta blocker
propranolol [36], suggesting a possible dual inhibition of VEGF
when beta blockers are given together with bevacizumab.
Clinical impact of beta blockers in cancer patients has been the
focus of several large clinical and epidemiological studies, and
these drugs can significantly reduce cancer progression and
mortality [37–40], and might represent a promising drug
combination with bevacizumab. Interestingly therefore, we
found beta blocker use together with bevacizumab to be
significantly associated with disease control. Still, this trial was
not designed to analyze beta blocker use independently from
hypertension, and the data must be interpreted with caution.
[41]
In conclusion, bevacizumab monotherapy yielded promising
data regarding disease control, progression free survival and
overall survival in patients with metastatic melanoma, and the
responders were typically characterized by induced hypertension
early during therapy.
Figure 4. Kaplan Meyer plots of progression free survival (PFS) (A) and overall survival (OS) (B) in 35 metastatic melanoma patients
treated with bevacizumab monotherapy. Early hypertension (EH) was significantly associated with PFS (C) and OS (D).
doi:10.1371/journal.pone.0038364.g004
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